The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
The SWI/SNF complex in cancer — biology, biomarkers and therapy
Open accessAbstract
Cancer genome-sequencing studies have revealed a remarkably high prevalence of mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes, with nearly 25% of all cancers harbouring aberrations in one or more of these genes. A role for such aberrations in tumorigenesis is evidenced by cancer predisposition in both carriers of germline loss-of-function mutations and genetically engineered mouse models with inactivation of any of several SWI/SNF subunits. Whereas many of the most frequently mutated oncogenes and tumour-suppressor genes have been studied for several decades, the cancer-promoting role of mutations in SWI/SNF genes has been recognized only more recently, and thus comparatively less is known about these alterations. Consequently, increasing research interest is being focused on understanding the prognostic and, in particular, the potential therapeutic implications of mutations in genes encoding SWI/SNF subunits. Herein, we review the burgeoning data on the mechanisms by which mutations affecting SWI/SNF complexes promote cancer and describe promising emerging opportunities for targeted therapy, including immunotherapy with immune-checkpoint inhibitors, presented by these mutations. We also highlight ongoing clinical trials open specifically to patients with cancers harbouring mutations in certain SWI/SNF genes. Mutations in genes encoding subunits of the SWI/SNF chromatin-remodelling complexes occur in almost 25% of all cancers. Herein, Mittal and Roberts discuss the mechanisms by which these mutations might promote cancer and describe the associated vulnerabilities that provide opportunities for targeted therapy or immunotherapy with immune-checkpoint inhibitors. At least nine different genes encoding subunits of the SWI/SNF family of chromatin-remodelling complexes are recurrently mutated in cancer, and these mutations are collectively present in nearly 25% of cancers. Mutations in specific SWI/SNF genes are enriched in particular cancer types, suggesting differential roles for individual SWI/SNF components; consistent with this hypothesis, different SWI/SNF gene mutations confer distinct cancer vulnerabilities in mouse models. The tumour-suppressor activity of the SWI/SNF chromatin-regulatory complexes is most likely attributable to their roles in facilitating transcription factor function, which is central to cell-fate specification; however, roles of the complexes in facilitating DNA repair might also contribute. The identification of potential therapeutic vulnerabilities that arise from SWI/SNF gene mutations is leading to new areas of clinical investigation, including studies of immunotherapy in addition to kinase inhibitors and agents targeting mediators of DNA damage repair.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationComprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
The Biology of Chromatin Remodeling Complexes
Clapier, C. R., & Cairns, B. R. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.062706.153223 · Cited by 2,380
Burnside, R. D. (2015) · Cytogenetic and Genome Research · doi:10.1159/000438708 · Cited by 1,946
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
Versteege, I., Sévenet, N., Lange, J., Rousseau-Merck, M.-F., Ambros, P., Handgretinger, R., Aurias, A., & Delattre, O. (1998) · Nature · doi:10.1038/28212 · Cited by 1,556
Morin, R. D., Johnson, N. A., Severson, T. M., Mungall, A. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,521
Kim, K. H., & Roberts, C. W. M. (2016) · Nature Medicine · doi:10.1038/nm.4036 · Cited by 1,471
Self-citationKadoch, C., Hargreaves, D. C., Hodges, C., Elias, L., Ho, L., Ranish, J., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,458
SWI/SNF nucleosome remodellers and cancer
Wilson, B. G., & Roberts, C. W. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3068 · Cited by 1,282
Self-citationMcDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0053-3 · Cited by 1,260
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Miao, D., Margolis, C. A., Gao, W., Voss, M. H., Li, W., Martini, D. J., Norton, C., Bossé, D., Wankowicz, S. M., Cullen, D., et al. (2018) · Science · doi:10.1126/science.aan5951 · Cited by 1,249
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Oncogenic Transcription Factors in the Human Acute Leukemias
Look, A. T. (1997) · Science · doi:10.1126/science.278.5340.1059 · Cited by 1,187
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,123
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
Tamkun, J. W., Deuring, R., Scott, M. P., Kissinger, M., Pattatucci, A. M., Kaufman, T. C., & Kennison, J. A. (1992) · Cell · doi:10.1016/0092-8674(92)90191-e · Cited by 971
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
Purification and biochemical heterogeneity of the mammalian SWI-SNF complex.
Wang, W., Côté, J., Xue, Y., Zhou, S., Khavari, P. A., Biggar, S. R., Muchardt, C., Kalpana, G. V., Goff, S. P., Yaniv, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00921.x · Cited by 837
Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors.
Biegel, J. A., Zhou, J. Y., RORKE, L. B., Stenstrom, C., Wainwright, L. M., & Fogelgren, B. (1999) · PubMed · Cited by 836
Knutson, S. K., Warholic, N. M., Wigle, T. J., Klaus, C. R., Allain, C. J., Raimondi, A., Porter Scott, M., Chesworth, R., Moyer, M. P., Copeland, R. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303800110 · Cited by 789
Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex
Kwon, H., Imbalzano, A. N., Khavari, P. A., Kingston, R. E., & Green, M. R. (1994) · Nature · doi:10.1038/370477a0 · Cited by 779
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776
Modular Organization and Assembly of SWI/SNF Family Chromatin Remodeling Complexes
Mashtalir, N., D’Avino, A. R., Michel, B. C., Luo, J., Pan, J., Otto, J. E., Zullow, H. J., McKenzie, Z. M., Kubiak, R. L., St. Pierre, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.032 · Cited by 731
Genomic Evolution of Breast Cancer Metastasis and Relapse
Yates, L. R., Knappskog, S., Wedge, D., Farmery, J. H. R., Gonzalez, S., Martincorena, I., Alexandrov, L. B., Van Loo, P., Haugland, H. K., Lilleng, P. K., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.005 · Cited by 665
Epigenetic Antagonism between Polycomb and SWI/SNF Complexes during Oncogenic Transformation
Wilson, B. G., Wang, X., Shen, X., McKenna, E. S., Lemieux, M. E., Cho, Y.-J., Koellhoffer, E. C., Pomeroy, S. L., Orkin, S. H., & Roberts, C. W. M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.09.006 · Cited by 654
Self-citationItaliano, A., Soria, J.-C., Toulmonde, M., Michot, J.-M., Lucchesi, C., Varga, A., Coindre, J.-M., Blakemore, S. J., Clawson, A., Suttle, B., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30145-1 · Cited by 627
Peterson, C. L., & Herskowitz, I. (1992) · Cell · doi:10.1016/0092-8674(92)90192-f · Cited by 595
Neigeborn, L., & Carlson, M. (1984) · Genetics · doi:10.1093/genetics/108.4.845 · Cited by 584
The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers
Shain, A. H., & Pollack, J. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055119 · Cited by 576
Johann, P. D., Erkek, S., Zapatka, M., Kerl, K., Buchhalter, I., Hovestadt, V., Jones, D. T. W., Sturm, D., Hermann, C., Segura Wang, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.001 · Cited by 571
Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Ntziachristos, P., Tsirigos, A., Vlierberghe, P. V., Nedjic, J., Trimarchi, T., Flaherty, M. S., Ferres-Marco, D., da Ros, V., Tang, Z., Siegle, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2651 · Cited by 526
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0849 · Cited by 522
Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome
Tsurusaki, Y., Okamoto, N., Ohashi, H., Kosho, T., Imai, Y., Hibi-Ko, Y., Kaname, T., Naritomi, K., Kawame, H., Wakui, K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2219 · Cited by 518
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias
for The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project, Andersson, A. K., Ma, J., Wang, J., Chen, X., Gedman, A. L., Dang, J., Nakitandwe, J., Holmfeldt, L., Parker, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3230 · Cited by 490
Kadoch, C., & Crabtree, G. R. (2013) · Cell · doi:10.1016/j.cell.2013.02.036 · Cited by 484
Dosage-dependent modifiers of polycomb and antennapedia mutations in Drosophila.
Kennison, J. A., & Tamkun, J. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.21.8136 · Cited by 468
Five SWI genes are required for expression of the HO gene in yeast
Stern, M., Jensen, R., & Herskowitz, I. (1984) · Journal of Molecular Biology · doi:10.1016/0022-2836(84)90315-2 · Cited by 461
Constitutional Mutations of the hSNF5/INI1 Gene Predispose to a Variety of Cancers
Sévenet, N., Sheridan, E., Amram, D., Schneider, P., Handgretinger, R., & Delattre, O. (1999) · The American Journal of Human Genetics · doi:10.1086/302639 · Cited by 450
Genomic correlates of response to immune checkpoint blockade
Keenan, T. E., Burke, K. P., & Van Allen, E. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0382-x · Cited by 448
Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice
Roberts, C. W. M., Galusha, S. A., McMenamin, M. E., Fletcher, C. D. M., & Orkin, S. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250492697 · Cited by 433
Self-citationA remarkably simple genome underlies highly malignant pediatric rhabdoid cancers
Lee, R. S., Stewart, C., Carter, S. L., Ambrogio, L., Cibulskis, K., Sougnez, C., Lawrence, M. S., Auclair, D., Mora, J., Golub, T. R., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64400 · Cited by 428
Self-citationThe SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers
Alver, B. H., Kim, K. H., Lu, P., Wang, X., Manchester, H. E., Wang, W., Haswell, J. R., Park, P. J., & Roberts, C. W. M. (2017) · Nature Communications · doi:10.1038/ncomms14648 · Cited by 427
Self-citationMichel, B. C., D’Avino, A. R., Cassel, S. H., Mashtalir, N., McKenzie, Z. M., McBride, M. J., Valencia, A. M., Zhou, Q., Bocker, M., Soares, L. M. M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0221-1 · Cited by 422
Hoffman, G. R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316793111 · Cited by 421
Self-citationARID1B is a specific vulnerability in ARID1A-mutant cancers
Helming, K. C., Wang, X., Wilson, B. G., Vazquez, F., Haswell, J. R., Manchester, H. E., Kim, Y., Kryukov, G. V., Ghandi, M., Aguirre, A. J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3480 · Cited by 418
Self-citationThe Many Roles of BAF (mSWI/SNF) and PBAF Complexes in Cancer
Hodges, C., Kirkland, J. G., & Crabtree, G. R. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026930 · Cited by 414
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
Klochendler‐Yeivin, A., Fiette, L., Barra, J., Muchardt, C., Babinet, C., & Yaniv, M. (2000) · EMBO reports · doi:10.1093/embo-reports/kvd129 · Cited by 406
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kim, K. H., Kim, W., Howard, T. P., Vazquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 406
Self-citationCairns, B. R., Kim, Y. J., Sayre, M. H., Laurent, B. C., & Kornberg, R. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1950 · Cited by 390
Ramos, P., Karnezis, A. N., Craig, D. W., Sekulic, A., Russell, M. L., Hendricks, W. P. D., Corneveaux, J. J., Barrett, M. T., Shumansky, K., Yang, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.2928 · Cited by 387
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382
The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes
Huether, R., Dong, L., Chen, X., Wu, G., Parker, M., Wei, L., Ma, J., Edmonson, M. N., Hedlund, E. K., Rusch, M. C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4630 · Cited by 379
Reisman, D., Sciarrotta, J., Wang, W., Funkhouser, W. K., & Weissman, B. E. (2003) · PubMed · Cited by 378
SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation
Wang, X., Lee, R. S., Alver, B. H., Haswell, J. R., Wang, S., Mieczkowski, J., Drier, Y., Gillespie, S. M., Archer, T. C., Wu, J. N., et al. (2017) · Nature Genetics · doi:10.1038/ng.3746 · Cited by 370
Self-citationARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice
Mathur, R., Alver, B. H., San Roman, A. K., Wilson, B. G., Wang, X., Agoston, A. T., Park, P. J., Shivdasani, R. A., & Roberts, C. W. M. (2017) · Nature Genetics · doi:10.1038/ng.3744 · Cited by 360
Self-citationRoberts, C. W. M., Leroux, M. M., Fleming, M. D., & Orkin, S. H. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00185-x · Cited by 333
Self-citationMutations in EZH2 Cause Weaver Syndrome
Gibson, W. T., Hood, R. L., Zhan, S. H., Bulman, D. E., Fejes, A. P., Moore, R., Mungall, A. J., Eydoux, P., Babul-Hirji, R., An, J., et al. (2012) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.11.018 · Cited by 321
Ogiwara, H., Ui, A., Otsuka, A., Satoh, H., Yokomi, I., Nakajima, S., Yasui, A., Yokota, J., & Kohno, T. (2011) · Oncogene · doi:10.1038/onc.2010.592 · Cited by 304
LncBRM initiates YAP1 signalling activation to drive self-renewal of liver cancer stem cells
Zhu, P., Wang, Y., Wu, J., Huang, G., Liu, B., Ye, B., Du, Y., Gao, G., Tian, Y., He, L., et al. (2016) · Nature Communications · doi:10.1038/ncomms13608 · Cited by 302
Dynamics of BAF–Polycomb complex opposition on heterochromatin in normal and oncogenic states
Kadoch, C., Williams, R. T., Calarco, J. P., Miller, E. L., Weber, C. M., Braun, S. M. G., Pulice, J. L., Chory, E. J., & Crabtree, G. R. (2017) · Nature Genetics · doi:10.1038/ng.3734 · Cited by 296
Disruption of Ini1 Leads to Peri-Implantation Lethality and Tumorigenesis in Mice
Guidi, C. J., Sands, A. T., Zambrowicz, B. P., Turner, T. K., Demers, D. A., Webster, W., Smith, T. W., Imbalzano, A. N., & Jones, S. N. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.10.3598-3603.2001 · Cited by 295
Oike, T., Ogiwara, H., Tominaga, Y., Ito, K., Ando, O., Tsuta, K., Mizukami, T., Shimada, Y., Isomura, H., Komachi, M., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4593 · Cited by 294
Nakayama, R. T., Pulice, J. L., Valencia, A. M., McBride, M. J., McKenzie, Z. M., Gillespie, M. A., Ku, W. L., Teng, M., Cui, K., Williams, R. T., et al. (2017) · Nature Genetics · doi:10.1038/ng.3958 · Cited by 291
Kakarougkas, A., Ismail, A., Chambers, A. L., Riballo, E., Herbert, A. D., Künzel, J., Löbrich, M., Jeggo, P. A., & Downs, J. A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.06.028 · Cited by 290
Mammalian SWI/SNF complexes facilitate DNA double‐strand break repair by promoting γ‐H2AX induction
Park, J., Park, E., Lee, H., Kim, S. J., Hur, S., Imbalzano, A. N., & Kwon, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601291 · Cited by 278
Aster, J. C., Xu, L., Karnell, F. G., Patriub, V., Pui, J. C., & Pear, W. S. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7505-7515.2000 · Cited by 277
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma
McBride, M. J., Pulice, J. L., Beird, H. C., Ingram, D. R., D’Avino, A. R., Shern, J. F., Charville, G. W., Hornick, J. L., Nakayama, R. T., Garcia-Rivera, E. M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.002 · Cited by 273
BAF complexes facilitate decatenation of DNA by topoisomerase IIα
Dykhuizen, E. C., Hargreaves, D. C., Miller, E. L., Cui, K., Korshunov, A., Kool, M., Pfister, S., Cho, Y.-J., Zhao, K., & Crabtree, G. R. (2013) · Nature · doi:10.1038/nature12146 · Cited by 269
Selectivity of chromatin-remodelling cofactors for ligand-activated transcription
Lemon, B., Inouye, C., King, D. S., & Tjian, R. (2001) · Nature · doi:10.1038/414924a · Cited by 262
Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway
Jagani, Z., Mora-Blanco, E. L., Sansam, C. G., McKenna, E. S., Wilson, B., Chen, D., Klekota, J., Tamayo, P., Nguyen, P. T. L., Tolstorukov, M., et al. (2010) · Nature Medicine · doi:10.1038/nm.2251 · Cited by 251
Self-citationTorchia, J., Golbourn, B., Feng, S., Ho, K. C., Sin-Chan, P., Vasiljevic, A., Norman, J. D., Guilhamon, P., Garzia, L., Agamez, N. R., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.11.003 · Cited by 251
Papillon, J. P. N., Nakajima, K., Adair, C. D., Hempel, J., Jouk, A. O., Karki, R. G., Mathieu, S., Möbitz, H., Ntaganda, R., Smith, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01318 · Cited by 244
Martens, J. A., Wu, P.-Y. J., & Winston, F. (2005) · Genes & Development · doi:10.1101/gad.1367605 · Cited by 240
Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome
Van Houdt, J. K. J., Nowakowska, B. A., Sousa, S. B., van Schaik, B. D. C., Seuntjens, E., Avonce, N., Sifrim, A., Abdul-Rahman, O. A., van den Boogaard, M.-J. H., Bottani, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.1105 · Cited by 239
Theodoulou, N. H., Bamborough, P., Bannister, A. J., Becher, I., Bit, R. A., Che, K. H., Chung, C.-W., Dittmann, A., Drewes, G., Drewry, D. H., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00256 · Cited by 235
Molecular subgrouping of atypical teratoid/rhabdoid tumors—a reinvestigation and current consensus
Ho, B., Johann, P. D., Grabovska, Y., De Dieu Andrianteranagna, M. J., Yao, F., Frühwald, M., Hasselblatt, M., Bourdeaut, F., Williamson, D., Huang, A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz235 · Cited by 235
Alpsoy, A., & Dykhuizen, E. C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001065 · Cited by 227
Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor
Bourdeaut, F., Lequin, D., Brugières, L., Reynaud, S., Dufour, C., Doz, F., André, N., Stephan, J.-L., Pérel, Y., Oberlin, O., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1795 · Cited by 224
Karnezis, A. N., Wang, Y., Ramos, P., Hendricks, W. P., Oliva, E., D'Angelo, E., Prat, J., Nucci, M. R., Nielsen, T. O., Chow, C., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4633 · Cited by 217
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Brien, G. L., Remillard, D., Shi, J., Hemming, M. L., Chabon, J., Wynne, K., Dillon, E. T., Cagney, G., Van Mierlo, G., Baltissen, M. P., et al. (2018) · eLife · doi:10.7554/elife.41305 · Cited by 213
Gatchalian, J., Malik, S., Ho, J., Lee, D.-S., Kelso, T. W. R., Shokhirev, M. N., Dixon, J. R., & Hargreaves, D. C. (2018) · Nature Communications · doi:10.1038/s41467-018-07528-9 · Cited by 213
Betz, B. L., Strobeck, M. W., Reisman, D. N., Knudsen, E. S., & Weissman, B. E. (2002) · Oncogene · doi:10.1038/sj.onc.1205706 · Cited by 212
Wang, X., Wang, S., Troisi, E. C., Howard, T. P., Haswell, J. R., Wolf, B. K., Hawk, W. H., Ramos, P., Oberlick, E. M., Tzvetkov, E. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09891-7 · Cited by 212
Self-citationGibson, W. J., Hoivik, E. A., Halle, M. K., Taylor-Weiner, A., Cherniack, A. D., Berg, A., Holst, F., Zack, T. I., Werner, H. M. J., Staby, K. M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3602 · Cited by 206
Bosse, T., ter Haar, N. T., Seeber, L. M., Diest, P. J. V., Hes, F. J., Vasen, H. F., Nout, R. A., Creutzberg, C. L., Morreau, H., & Smit, V. T. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.96 · Cited by 204
Hasselblatt, M., Nagel, I., Oyen, F., Bartelheim, K., Russell, R. B., Schüller, U., Junckerstorff, R., Rosenblum, M., Alassiri, A. H., Rossi, S., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1323-x · Cited by 203
Drugging PI3K in cancer: refining targets and therapeutic strategies
Yap, T. A., Bjerke, L., Clarke, P. A., & Workman, P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.016 · Cited by 202
Mismatch Repair and Colon Cancer: Mechanisms and Therapies Explored
Li, S. K. H., & Martin, A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.02.003 · Cited by 191
Geoerger, B., Bourdeaut, F., DuBois, S. G., Fischer, M., Geller, J. I., Gottardo, N. G., Marabelle, A., Pearson, A. D. J., Modak, S., Cash, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2898 · Cited by 190
Dominant-negative SMARCA4 mutants alter the accessibility landscape of tissue-unrestricted enhancers
Hodges, H. C., Stanton, B. Z., Cermakova, K., Chang, C.-Y., Miller, E. L., Kirkland, J. G., Ku, W. L., Veverka, V., Zhao, K., & Crabtree, G. R. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-017-0007-3 · Cited by 190
Watanabe, R., Ui, A., Kanno, S.-I., Ogiwara, H., Nagase, T., Kohno, T., & Yasui, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3608 · Cited by 189
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
Xue, Y., Meehan, B., Fu, Z., Wang, X. Q. D., Fiset, P. O., Rieker, R., Levins, C., Kong, T., Zhu, X., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08380-1 · Cited by 187
SWI/SNF Chromatin-remodeling Factors: Multiscale Analyses and Diverse Functions
Euskirchen, G., Auerbach, R. K., & Snyder, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.309302 · Cited by 182
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
Hohmann, A. F., Martin, L. J., Minder, J. L., Roe, J.-S., Shi, J., Steurer, S., Bader, G., McConnell, D., Pearson, M., Gerstberger, T., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2115 · Cited by 180
Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade
Gu, Y.-F., Cohn, S., Christie, A., McKenzie, T., Wolff, N., Do, Q. N., Madhuranthakam, A. J., Pedrosa, I., Wang, T., Dey, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0292 · Cited by 176
Stop pulling my strings — what telomeres taught us about the DNA damage response
Lazzerini-Denchi, E., & Sfeir, A. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.43 · Cited by 170
Jelinic, P., Ricca, J., Van Oudenhove, E., Olvera, N., Merghoub, T., Levine, D. A., & Zamarin, D. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx277 · Cited by 168
Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors
Leruste, A., Tosello, J., Ramos, R. N., Tauziède-Espariat, A., Brohard, S., Han, Z.-Y., Beccaria, K., Andrianteranagna, M., Caudana, P., Nikolic, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.008 · Cited by 161
Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities
St. Pierre, R., & Kadoch, C. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.02.004 · Cited by 159
Wang, X., Sansam, C. G., Thom, C. S., METZGER, D., Evans, J. A., Nguyen, P. T. L., & Roberts, C. W. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0733 · Cited by 158
Self-citationSchick, S., Rendeiro, A. F., Runggatscher, K., Ringler, A., Boidol, B., Hinkel, M., Májek, P., Vulliard, L., Penz, T., Parapatics, K., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0477-9 · Cited by 156
Chun, H.-J. E., Lim, E. L., Heravi‐Moussavi, A., Saberi, S., Mungall, K., Bilenky, M., Carles, A., Tse, K., Shlafman, I., Zhu, K., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.009 · Cited by 153
Characterization of mammary tumors from Brg1 heterozygous mice
Bultman, S. J., Herschkowitz, J. I., Godfrey, V., Gebuhr, T. C., Yaniv, M., Perou, C. M., & Magnuson, T. (2007) · Oncogene · doi:10.1038/sj.onc.1210664 · Cited by 152
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition
Samartzis, E. P., Gutsche, K., Dedes, K. J., Fink, D. A., Stucki, M., & Imesch, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2092 · Cited by 148
Genome-Wide Transcriptional Regulation Mediated by Biochemically Distinct SWI/SNF Complexes
Raab, J. R., Resnick, S. J., & Magnuson, T. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005748 · Cited by 144
Park, Y., Chui, M. H., Rahmanto, Y. S., Yu, Z.-C., Shamanna, R. A., Bellani, M. A., Gaillard, S. L., Ayhan, A., Viswanathan, A., Seidman, M. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4222 · Cited by 141
Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes
Jiang, T., Chen, X., Su, C., Ren, S., & Zhou, C. (2019) · Journal of Cancer · doi:10.7150/jca.41296 · Cited by 133
Kurmasheva, R. T., Sammons, M. C., Favours, E., Wu, J., Kurmashev, D., Cosmopoulos, K., Keilhack, H., Klaus, C. R., Houghton, P. J., & Smith, M. A. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26218 · Cited by 129
Tagal, V., Wei, S., Zhang, W., Brekken, R. A., Posner, B. A., Peyton, M., Girard, L., Hwang, T., Wheeler, D. A., Minna, J. D., et al. (2017) · Nature Communications · doi:10.1038/ncomms14098 · Cited by 129
Xue, Y., Meehan, B., Macdonald, E. A., Venneti, S., Wang, X. Q. D., Witkowski, L., Jelinic, P., Kong, T., Martínez, D., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-06958-9 · Cited by 128
Han, Z., Richer, W., Fréneaux, P., Chauvin, C., Lucchesi, C., Guillemot, D., Grison, C., Lequin, D., Pierron, G., Masliah‐Planchon, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10421 · Cited by 126
Chun, H.-J. E., Johann, P. D., Milne, K., Zapatka, M., Büllesbach, A., Ishaque, N., Iskar, M., Erkek, S., Wei, L. L., Tessier‐Cloutier, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.013 · Cited by 124
BAF180 Promotes Cohesion and Prevents Genome Instability and Aneuploidy
Brownlee, P. M., Chambers, A. L., Cloney, R., Bianchi, A., & Downs, J. A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.012 · Cited by 120
Functional loss of ARID1A is tightly associated with high PD‐L1 expression in gastric cancer
Kim, Y., Ahn, J. M., Bae, W. J., Sung, C. O., & Lee, D. (2019) · International Journal of Cancer · doi:10.1002/ijc.32140 · Cited by 120
Mossé, Y. P., Fox, E., Teachey, D. T., Reid, J. M., Safgren, S. L., Carol, H., Lock, R. B., Houghton, P. J., Smith, M. A., Hall, D. C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2675 · Cited by 119
BRG1 promotes DNA double-strand break repair by facilitating the replacement of RPA with RAD51
Qi, W., Wang, R., Chen, H., Wang, X., Xiao, T., Boldogh, I. R., Ba, X., Han, L., & Zeng, X. (2014) · Journal of Cell Science · doi:10.1242/jcs.159103 · Cited by 116
Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer
Fukumoto, T., Park, P. H., Wu, S., Fatkhutdinov, N., Karakashev, S. V., Nacarelli, T., Kossenkov, A. V., Speicher, D. W., Jean, S., Zhang, L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.019 · Cited by 112
BRG1 Is a Prognostic Marker and Potential Therapeutic Target in Human Breast Cancer
Bai, J., Mei, P.-J., Zhang, C., Chen, F., Li, C., Pan, Z., Liu, H., & Zheng, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059772 · Cited by 101
Savas, S., & Skardasi, G. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.009 · Cited by 100
Yamamoto, S., Tsuda, H., Takano, M., Tamai, S., & Matsubara, O. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1169-8 · Cited by 98
T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice.
Condorelli, G., Facchiano, F., Valtieri, M., Proietti, E., Vitelli, L., Lulli, V., Huebner, K., Peschle, C., & Croce, C. M. (1996) · PubMed · Cited by 97
Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer
Ding, Y., Li, N., Dong, B., Guo, W., Wei, H., Chen, Q., Yuan, H., Han, Y., Chang, H., Kan, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci123557 · Cited by 97
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors
Carugo, A., Minelli, R., Sapio, L., Soeung, M., Carbone, F., Robinson, F. S., Tepper, J., Chen, Z., Lovisa, S., Svelto, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.006 · Cited by 97
Self-citationSMARCB1 mutations in schwannomatosis and genotype correlations with rhabdoid tumors
Smith, M. J., Wallace, A. J., Bowers, N. L., Eaton, H., & Evans, D. G. (2014) · Cancer Genetics · doi:10.1016/j.cancergen.2014.04.001 · Cited by 94
Brownlee, P. M., Meisenberg, C., & Downs, J. A. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.023 · Cited by 94
Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib
Miller, R. E., Brough, R., Bajrami, I., Williamson, C. T., McDade, S. S., Campbell, J., Kigozi, A., Rafiq, R., Pemberton, H. N., Natrajan, R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0554 · Cited by 93
Lü, C., & Allis, C. D. (2017) · Nature Genetics · doi:10.1038/ng.3779 · Cited by 93
Erkek, S., Johann, P. D., Finetti, M. A., Drosos, Y., Chou, H.-C., Zapatka, M., Sturm, D., Jones, D., Korshunov, A., Ryzhova, M. V., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.014 · Cited by 93
Self-citationInhibition of MYC by the SMARCB1 tumor suppressor
Weissmiller, A. M., Wang, J., Lorey, S. L., Howard, G. C., Martinez, E., Liu, Q., & Tansey, W. P. (2019) · Nature Communications · doi:10.1038/s41467-019-10022-5 · Cited by 92
Chen, Y., Zhang, H., Xu, Z., Tang, H., Geng, A., Cai, B., Su, T., Shi, J., Jiang, C., Tian, X., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz592 · Cited by 86
TCR-dependent transformation of mature memory phenotype T cells in mice
Wang, X., Werneck, M. B. F., Wilson, B. G., Kim, H. J., Kluk, M., Thom, C. S., Wischhusen, J. W., Evans, J. A., Jesneck, J. L., Nguyen, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci37210 · Cited by 82
Self-citationKawano, S., Grassian, A. R., Tsuda, M., Knutson, S. K., Warholic, N. M., Kuznetsov, G., Xu, S., Xiao, Y., Pollock, R. M., Smith, J. S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158888 · Cited by 75
Lü, B., & Shi, H. (2019) · Journal of Cancer · doi:10.7150/jca.26978 · Cited by 74
Hu, Z., Zhou, J., Jiang, J., Yuan, J., Zhang, Y., Wei, X., Loo, N., Wang, Y., Pan, Y., Zhang, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08554-x · Cited by 73
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors
Howard, T. P., Arnoff, T. E., Song, M. R., Giacomelli, A. O., Wang, X., Hong, A. L., Dharia, N. V., Wang, S., Vázquez, F., Pham, M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3066 · Cited by 73
Self-citationLang, J. D., Hendricks, W. P. D., Yin, H., Kiefer, J. M., Ramos, P. M., Sharma, R., Pirrotte, P., Raupach, E. A., Sereduk, C., Tang, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1928 · Cited by 73
Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells
Venkataraman, S., Alimova, I. N., Tello, T. L., Harris, P. S., Knipstein, J. A., Donson, A. M., Foreman, N. K., Liu, A. K., & Vibhakar, R. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0795-y · Cited by 72
ARID1A promotes genomic stability through protecting telomere cohesion
Zhao, B., Lin, J., Rong, L., Wu, S., Deng, Z., Fatkhutdinov, N., Zundell, J. A., Fukumoto, T., Liu, Q., Kossenkov, A. V., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12037-4 · Cited by 72
SWI/SNF-Compromised Cancers Are Susceptible to Bromodomain Inhibitors
Shorstova, T., Marques, M., Su, J., Johnston, J., Kleinman, C. L., Hamel, N., Huang, S., Alaoui‐Jamali, M. A., Foulkes, W. D., & Witcher, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1545 · Cited by 71
Cho, H., Kim, J. S.-Y., Chung, H., Perry, C. D., Lee, H.-J., & Kim, J. (2013) · Human Pathology · doi:10.1016/j.humpath.2012.11.007 · Cited by 67
Hereditary SWI/SNF complex deficiency syndromes
Agaimy, A., & Foulkes, W. D. (2018) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2018.01.002 · Cited by 67
Molin, M. D., Hong, S., Hebbar, S., Sharma, R. B., Scrimieri, F., de Wilde, R. F., Mayo, S. C., Goggins, M., Wolfgang, C. L., Schulick, R. D., et al. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.06.009 · Cited by 66
Alimova, I. N., Pierce, A. M., Danis, E. P., Donson, A. M., Birks, D. K., Griesinger, A. M., Foreman, N. K., Santi, M., Soucek, L., Venkataraman, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31873 · Cited by 65
Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors
Wong, J. P.-M., Todd, J. R., Finetti, M. A., McCarthy, F., Broncel, M., Vyse, S., Luczynski, M. T., Crosier, S., Ryall, K. A., Holmes, K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.005 · Cited by 62
A pan-cancer analysis of prognostic genes
Anaya, J., Reon, B. J., Chen, W., Bekiranov, S., & Dutta, A. (2016) · PeerJ · doi:10.7717/peerj.1499 · Cited by 62
Knipstein, J. A., Birks, D. K., Donson, A. M., Alimova, I., Foreman, N. K., & Vibhakar, R. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor208 · Cited by 60
Zhang, Q., Yan, H., Wang, J., Cui, S., Wang, X., Jiang, Y.-H., Li, F., Yang, P., & Liu, F. (2016) · Oncotarget · doi:10.18632/oncotarget.10060 · Cited by 58
Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers
Forrest, S. J., Al‐Ibraheemi, A., Doan, D., Ward, A., Clinton, C. M., Putra, J., Pinches, R. S., Kadoch, C., Chi, S. N., DuBois, S. G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3089 · Cited by 58
Orlando, K. A., Nguyen, V. Q., Raab, J. R., Walhart, T. A., & Weissman, B. E. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1605905 · Cited by 57
Prognostic role of ARID1A negative expression in gastric cancer
Ashizawa, M., Saito, M., Min, A. K. T., Ujiie, D., Saito, K., Sato, T., Kikuchi, T., Okayama, H., Fujita, S., Endo, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43293-5 · Cited by 56
SWI/SNF Complex-Deficient Soft Tissue Neoplasms
Agaimy, A. (2019) · Surgical pathology clinics · doi:10.1016/j.path.2018.10.006 · Cited by 54
Endo, M., Yasui, K., Zen, Y., Gen, Y., Zen, K., Tsuji, K., Dohi, O., Mitsuyoshi, H., Tanaka, S., Taniwaki, M., et al. (2012) · Liver International · doi:10.1111/liv.12005 · Cited by 50
The genetic alteration spectrum of the SWI/SNF complex: The oncogenic roles of BRD9 and ACTL6A
Sima, X., He, J., Peng, J., Xu, Y., Zhang, F., & Deng, L. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222305 · Cited by 48
Chauvin, C., Leruste, A., Tauziède‐Espariat, A., Andrianteranagna, M. J. D. D., Surdez, D., Lescure, A., Han, Z., Anthony, E., Richer, W., Baulande, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.076 · Cited by 47
The silencing of the SWI/SNF subunit and anticancer gene BRM in Rhabdoid tumors
Kahali, B., Yu, J., Marquez, S. B., Thompson, K. W., Liang, S. Y., Lü, L., & Reisman, D. (2014) · Oncotarget · doi:10.18632/oncotarget.1945 · Cited by 46
Chabanon, R. M., Morel, D., & Postel-Vinay, S. C. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.018 · Cited by 46
Oberlick, E. M., Rees, M. G., Seashore-Ludlow, B. A., Vázquez, F., Nelson, G. M., Dharia, N. V., Weir, B. A., Tsherniak, A., Ghandi, M., Krill-Burger, J. M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.021 · Cited by 43
Self-citationBRG1 promotes hepatocarcinogenesis by regulating proliferation and invasiveness
Kaufmann, B. K., Wang, B., Zhong, S., Laschinger, M., Patil, P., Lu, M., Aßfalg, V., Cheng, Z., Frieß, H., Hüser, N., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180225 · Cited by 32
Translational genomics of malignant rhabdoid tumours: Current impact and future possibilities
Finetti, M. A., Grabovska, Y., Bailey, S., & Williamson, D. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.017 · Cited by 32
Somatic drivers of B-ALL in a model of ETV6-RUNX1; Pax5 +/− leukemia
van der Weyden, L., Giotopoulos, G., Wong, K., Rust, A. G., Robles‐Espinoza, C. D., Osaki, H., Huntly, B. J. P., & Adams, D. J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1586-1 · Cited by 30
Buglioni, S., Melucci, E., Sperati, F., Pallocca, M., Terrenato, I., Nicola, F. D., Goeman, F., Casini, B., Amoreo, C. A., Gallo, E., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1457602 · Cited by 20
Gm, C. (1985) · PubMed · Cited by 15
The Management of Ureteral Stones
Nourse, M. H. (1966) · JAMA · doi:10.1001/jama.1966.03110250084024 · Cited by 8
Cited by
Biomolecular Condensates and Cancer
Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 327
Hepatocellular carcinoma: old friends and new tricks
Kim, E., & Viatour, P. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00527-1 · Cited by 307
Xu, X., Peng, Q., Jiang, X., Tan, S., Yang, Y., Yang, W., Han, Y., Chen, Y., Oyang, L., Lin, J., et al. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01020-1 · Cited by 276
Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg
Fernández-Barrena, M. G., Arechederra, M., Colyn, L., Berasain, C., & Avila, M. A. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100167 · Cited by 126
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
Metadata
- Authors
- Mittal, P., & Roberts, C. W. M.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2020-04-17
- Volume
- 17
- Issue
- 7
- Pages
- 435-448
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3016379099
- Cited by
- 690
- References
- 171
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.